认知
重性抑郁障碍
医学
试制试验
认知测验
数字符号替换试验
萧条(经济学)
心理学
听力学
精神科
认知障碍
安慰剂
宏观经济学
病理
经济
替代医学
作者
Roger S. McIntyre,Michael W. Best,Christopher R. Bowie,Nicole E. Carmona,S. Danielle,Yena Lee,Mehala Subramaniapillai,Rodrigo B. Mansur,Harry Barry,Bernhard T. Baune,Larry Culpepper,Philippe Fossati,Tracy L. Greer,Catherine J. Harmer,Esther Klag,Raymond W. Lam,Hans‐Ulrich Wïttchen,John Harrison
摘要
To validate the THINC-integrated tool (THINC-it)-a freely available, patient-administered, computerized screening tool integrating subjective and objective measures of cognitive function in adults with major depressive disorder (MDD).Subjects aged 18 to 65 years (n = 100) with recurrent MDD experiencing a major depressive episode of at least moderate severity were evaluated and compared to age-, sex-, and education-matched healthy controls (n = 100). Between January and June 2016, subjects completed the THINC-it, which includes variants of the Choice Reaction Time Identification Task (IDN), One-Back Test, Digit Symbol Substitution Test, Trail Making Test-Part B, and the Perceived Deficits Questionnaire for Depression-5-item (PDQ-5-D).The THINC-it required approximately 10 to 15 minutes for administration and was capable of detecting cognitive deficits in adults with MDD. A total of 44.4% of adults with MDD exhibited cognitive performance at ≥ 1.0 SD below that of healthy controls on standardized mean scores of the THINC-it. Concurrent validity of the overall tool, based on a calculated composite score, was acceptable (r = 0.539, P < .001). Concurrent validity of the component tests ranged from -0.083 (IDN) to 0.929 (PDQ-5-D). Qualitative survey results indicated that there was a high level of satisfaction and perceived value in administering the THINC-it regarding its impact on the appropriateness and quality of care being received.The THINC-it is a valid and sensitive tool for detecting cognitive dysfunction in adults with MDD that is free, easy to use, and rapidly administered. The THINC-it should be incorporated into the assessment and measurement of all patients with MDD, particularly among those with enduring functional impairment.ClinicalTrials.gov identifier: NCT02508493.
科研通智能强力驱动
Strongly Powered by AbleSci AI